Welcome to Pangaea insights

Our collective intelligence provides an unrivalled breadth and depth of knowledge.

Pangaea’s ongoing relationships with key industry stakeholders facilitate continuous updates and dissemination of relevant market intelligence. Check back often for new posts!

Insights on External Deployment by the Pharmaceutical Industry

August 13, 2019
The ever-changing Canadian health care environment has forced the pharmaceutical industry to rethink external deployment.

Pangaea Express: Announcement of Upcoming Patented Medicines Regulations Publication

August 9, 2019
Health Canada Officials provided an update today regarding the final Patented Medicines Regulations.

Pangaea Express: HHS Outlines Action Plan for Cross-Border Sales

August 1, 2019
“Canada does not support actions that could adversely affect the supply of prescription drugs in Canada and potentially raise costs of prescription drugs for Canadians.”

Pangaea Express: Promotional/Non-Promotional Messages & Activities for Health Products

July 12, 2019
The draft Guidance document regarding The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products has been posted by Health Canada.

Pangaea Express: Mandatory Reporting by Hospitals of Serious ADRs and MDIs

July 9, 2019
The Regulations regarding mandatory reporting of serious adverse drug reactions (ADRs) and medical device incidents (MDIs) by hospitals, proposed last summer, have now been adopted and will come into effect by December 16, 2019.

Pangaea Express: Federal Court Dismissal Of Alexion's Case

June 25, 2019
The Federal Court has dismissed Alexion’s request to review the PMPRB’s decision that SOLIRIS’ price was excessive.

Post-Market Surveillance of Medical Devices

June 25, 2019
Canada Gazette, Part I to amend the Regulations regarding the Post-market Surveillance of Medical Devices was posted June 15, 2019.

Pangaea Express: BC Bold on Biosimilars

May 28, 2019
It has been some time coming but the speculation is over now. BC is the first province to switch patients from certain innovator biologics to their biosimilars.

Pangaea Express: No more CADTH for Biosimilars

May 24, 2019
Biosimilars no longer need to be reviewed by CADTH.

Biologics and Biosimilars: Prescription Pathway and Points of Influence

May 17, 2019
For industry, the path of the biologic prescription, once written, may see a number of influence points that affect market share, marketing plans, patient support programs (PSPs) and prescribers.
← Prev
Page 2 of 10
Next →